Sponsors (2)
The bill strengthens safety oversight, reporting, and registration for compounding to reduce risks from large-scale or unsafe compounding, but it does so at the cost of reduced access for some patients, higher compliance costs for small and large compounders, and potential price or supply impacts.
Patients who rely on compounded drugs (e.g., chronic conditions, allergies, special dosing) will face reduced risk from unsafe or substandard compounded products because the bill limits large-scale duplication, requires reporting, establishes registration/inspection rules, and funds FDA oversight.
Licensed pharmacists, physicians, hospitals, and regulators gain clearer legal boundaries and better data because the bill defines when a compounded product is 'essentially a copy' and requires standardized reporting, improving targeted enforcement and regulatory predictability.
Hospitals and health systems get clearer registration rules and greater supply-chain transparency for large compounding facilities, supporting more consistent inspections and oversight of high-volume compounders.
Patients who need customized formulations (allergies, pediatric dosing, etc.) — and the pharmacists/physicians who serve them — may face reduced access, longer wait times, or short-term supply disruptions because the bill limits the number of compounded copies and newly required inspections/registrations.
Independent compounding pharmacies and small providers could lose revenue and face higher compliance costs from monthly/annual reporting, IT or administrative burdens, and potential limits on production volume.
Some demand may shift to commercial manufacturers (because exemptions tie to FDA-approved manufacturing), which could raise costs for patients who need alternatives not available from compounders.
Based on analysis of 5 sections of legislative text.
Limits compounding copies of commercial drugs, adds reporting and inspection rules for higher-volume compounders, and lets HHS set a base safety fee.
Introduced February 5, 2026 by James E. Banks · Last progress February 5, 2026
Limits how often pharmacists and physicians may compound copies of commercially available drugs, creates new reporting and inspection rules for higher-volume compounders, and lets the Secretary of Health and Human Services set a base fee to fund safety activities for compounded products. It narrows when a compounded product is treated as an exempt compounded drug by adding a 20-copy-per-month cap and detailed definitions of what counts as a copy, and it creates annual reporting requirements for certain out-of-state compounding. Adds a new definition and oversight tier for “large-scale outsourcing facilities” (those compounding more than 100 times per year), requiring an initial risk-based inspection and at least biennial reinspections; removes an existing registration exemption for outsourcing facilities; and replaces a fixed statutory fee token with a Secretary-determined base fee to support compound-safety activities. Some inspection/registration rules take effect six months after enactment; annual reporting starts with calendar year 2025.